ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 82 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2020. The put-call ratio across all filers is 1.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $412,952 | +66.3% | 136,288 | +27.9% | 0.00% | – |
| Q4 2022 | $248,253 | +589.6% | 106,546 | +464.7% | 0.00% | – |
| Q3 2022 | $36,000 | -68.7% | 18,869 | -55.7% | 0.00% | – |
| Q2 2022 | $115,000 | -91.1% | 42,601 | -90.2% | 0.00% | – |
| Q1 2022 | $1,296,000 | -60.6% | 434,714 | -48.6% | 0.00% | – |
| Q4 2021 | $3,293,000 | +66.6% | 846,380 | +83.7% | 0.00% | – |
| Q3 2021 | $1,977,000 | +924.4% | 460,861 | +624.2% | 0.00% | – |
| Q2 2021 | $193,000 | -63.8% | 63,635 | -60.3% | 0.00% | – |
| Q1 2021 | $533,000 | -45.1% | 160,362 | -41.4% | 0.00% | – |
| Q4 2020 | $971,000 | +1732.1% | 273,464 | +1525.3% | 0.00% | – |
| Q3 2020 | $53,000 | -72.7% | 16,825 | -84.2% | 0.00% | – |
| Q2 2020 | $194,000 | +165.8% | 106,181 | +45.6% | 0.00% | – |
| Q1 2020 | $73,000 | -79.0% | 72,925 | -56.4% | 0.00% | -100.0% |
| Q2 2019 | $348,000 | +411.8% | 167,188 | +1422.2% | 0.00% | – |
| Q3 2017 | $68,000 | -56.1% | 10,983 | -56.7% | 0.00% | -100.0% |
| Q3 2015 | $155,000 | – | 25,374 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |